4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B financing, with participation from 4BIO Capital. Read more at Orchard Therapeutics website.